Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Microbiology, pathogenesis, and epidemiology of infections due to group D streptococci (Streptococcus bovis/Streptococcus equinus complex)

INTRODUCTION

The Streptococcus bovis/Streptococcus equinus complex was created in 2003 after an extensive taxonomic revision [1]. This complex includes four major species (table 1) that all belong to group D streptococci (GDS). The published literature regarding these organisms does not always distinguish GDS to the biotype and/or subspecies level consistently.

The microbiology, pathogenesis, and epidemiology of these species will be reviewed here. The clinical manifestations, diagnosis, and treatment are discussed separately. (See "Clinical manifestations, diagnosis, and treatment of infections due to group D streptococci (Streptococcus bovis/Streptococcus equinus complex)".)

MICROBIOLOGY

Group D streptococci (GDS) are catalase-negative, gram-positive cocci that usually express the Lancefield group D antigen. Colonies are typically small and non-hemolytic on blood agar. Most GDS grow in 40 percent bile and hydrolyze esculin [2-4]. GDS can be distinguished from enterococci because they are PYR (pyrrolidonyl arylamidase) negative, fail to hydrolyze arginine, and are typically unable to grow in 6.5 percent salt broth [2-4]. However, the traditional tests for enterococci (salt tolerance, growth on bile esculin agar, and expression of Lancefield group D antigen) may not allow a definitive distinction between enterococci and GDS, so either additional biochemical testing or molecular techniques are needed to avoid misidentification [5].

A study of 58 blood isolates of GDS identified to the subspecies level by 16S rRNA sequencing noted the following species breakdown [4]:

29 strains were S. gallolyticus subsp. gallolyticus (50 percent)

    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Oct 30, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30:2369.
  2. Roberts RB. Streptococcal endocarditis: The viridans and beta hemolytic streptococci. In: Infective Endocarditis, Kaye D (Ed), Raven Press, Ltd, New York 1992. p.91.
  3. Moellering RC Jr, Watson BK, Kunz LJ. Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med 1974; 57:239.
  4. Beck M, Frodl R, Funke G. Comprehensive study of strains previously designated Streptococcus bovis consecutively isolated from human blood cultures and emended description of Streptococcus gallolyticus and Streptococcus infantarius subsp. coli. J Clin Microbiol 2008; 46:2966.
  5. Ellmerich S, Schöller M, Duranton B, et al. Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis 2000; 21:753.
  6. Dubrow R, Edberg S, Wikfors E, et al. Fecal carriage of Streptococcus bovis and colorectal adenomas. Gastroenterology 1991; 101:721.
  7. Klein RS, Recco RA, Catalano MT, et al. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med 1977; 297:800.
  8. Abdulamir AS, Hafidh RR, Mahdi LK, et al. Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer 2009; 9:403.
  9. Potter MA, Cunliffe NA, Smith M, et al. A prospective controlled study of the association of Streptococcus bovis with colorectal carcinoma. J Clin Pathol 1998; 51:473.
  10. Boleij A, Muytjens CM, Bukhari SI, et al. Novel clues on the specific association of Streptococcus gallolyticus subsp gallolyticus with colorectal cancer. J Infect Dis 2011; 203:1101.
  11. Biarc J, Nguyen IS, Pini A, et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis). Carcinogenesis 2004; 25:1477.
  12. Chirouze C, Patry I, Duval X, et al. Streptococcus bovis/Streptococcus equinus complex fecal carriage, colorectal carcinoma, and infective endocarditis: a new appraisal of a complex connection. Eur J Clin Microbiol Infect Dis 2013; 32:1171.
  13. Boleij A, Tjalsma H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis 2013; 13:719.
  14. Corredoira J, Alonso MP, Coira A, et al. Characteristics of Streptococcus bovis endocarditis and its differences with Streptococcus viridans endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27:285.
  15. Klein RS, Recco RA, Catalano MT, et al. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med 1977; 297:800.
  16. Klein RS, Warman SW, Knackmuhs GG, et al. Lack of association of Streptococcus bovis with noncolonic gastrointestinal carcinoma. Am J Gastroenterol 1987; 82:540.
  17. Burns CA, McCaughey R, Lauter CB. The association of Streptococcus bovis fecal carriage and colon neoplasia: possible relationship with polyps and their premalignant potential. Am J Gastroenterol 1985; 80:42.
  18. Hoen B, Briançon S, Delahaye F, et al. Tumors of the colon increase the risk of developing Streptococcus bovis endocarditis: case-control study. Clin Infect Dis 1994; 19:361.
  19. Norfleet RG, Mitchell PD. Streptococcus bovis does not selectively colonize colorectal cancer and polyps. J Clin Gastroenterol 1993; 17:25.
  20. Pfaller MA, Jones RN, Marshall SA, et al. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997; 29:259.
  21. Eggers S, Beuth J. Etiology and antibiotic susceptibility of bloodstream Streptococcus sp. Zentralbl Bakteriol 1992; 276:521.
  22. Ballet M, Gevigney G, Garé JP, et al. Infective endocarditis due to Streptococcus bovis. A report of 53 cases. Eur Heart J 1995; 16:1975.
  23. Murray HW, Roberts RB. Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med 1978; 138:1097.
  24. Selton-Suty C, Hoen B, Delahaye F, et al. Comparison of infective endocarditis in patients with and without previously recognized heart disease. Am J Cardiol 1996; 77:1134.
  25. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002; 162:90.
  26. Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002; 288:75.
  27. Hoen B, Chirouze C, Cabell CH, et al. Emergence of endocarditis due to group D streptococci: findings derived from the merged database of the International Collaboration on Endocarditis. Eur J Clin Microbiol Infect Dis 2005; 24:12.
  28. Durante-Mangoni E, Bradley S, Selton-Suty C, et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 2008; 168:2095.
  29. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169:463.
  30. Tripodi MF, Adinolfi LE, Ragone E, et al. Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor. Clin Infect Dis 2004; 38:1394.
  31. Giannitsioti E, Chirouze C, Bouvet A, et al. Characteristics and regional variations of group D streptococcal endocarditis in France. Clin Microbiol Infect 2007; 13:770.
  32. Pergola V, Di Salvo G, Habib G, et al. Comparison of clinical and echocardiographic characteristics of Streptococcus bovis endocarditis with that caused by other pathogens. Am J Cardiol 2001; 88:871.
  33. Zarkin BA, Lillemoe KD, Cameron JL, et al. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. Ann Surg 1990; 211:786.
  34. Duval X, Papastamopoulos V, Longuet P, et al. Definite streptococcus bovis endocarditis: characteristics in 20 patients. Clin Microbiol Infect 2001; 7:3.
  35. McKinsey DS, Ratts TE, Bisno AL. Underlying cardiac lesions in adults with infective endocarditis. The changing spectrum. Am J Med 1987; 82:681.
  36. Jain AK, Agarwal SK, el-Sadr W. Streptococcus bovis bacteremia and meningitis associated with Strongyloides stercoralis colitis in a patient infected with human immunodeficiency virus. Clin Infect Dis 1994; 18:253.
  37. Linder JD, Mönkemüller KE, Lazenby AJ, Wilcox CM. Streptococcus bovis bacteremia associated with Strongyloides stercoralis colitis. Gastrointest Endosc 2000; 52:796.